603998 Hunan Fangsheng Pharmaceutical
- 11.84
- +0.02+0.17%
Hunan Fangsheng Pharmaceutical News
Fangsheng Pharmaceutical (603998.SH): Symbiotic Investment plans to reduce its holdings by no more than 1.21%
Gelonghui, May 24, 丨 Fangsheng Pharmaceutical (603998.SH) announced that Symbiotic Investment plans to reduce its holdings of the company's shares by no more than 5,303,123 shares through centralized bidding or bulk transactions. Where holdings are reduced through centralized bidding transactions, it will be carried out within 3 months after 15 trading days from the date of disclosure of the holdings reduction plan announcement (that is, the holdings reduction period is from June 18, 2024 to September 16, 2024). Within any 90 consecutive calendar days, the total number of shares reduced will not exceed 1% of the total number of shares of the company. If holdings are reduced through bulk transactions, the holdings reduction plan will be announced
Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) Adds CN¥440m in Market Cap and Insiders Have a 38% Stake in That Gain
Key Insights Significant insider control over Hunan Fangsheng Pharmaceutical implies vested interests in company growth A total of 6 investors have a majority stake in the company with 52% ownership
Fangsheng Pharmaceutical (603998.SH): Net profit of 70.19 million yuan in the first quarter increased 10.04% year-on-year
On April 19, Ge Longhui Pharmaceutical (603998.SH) released its first quarter report. Operating revenue was 438 million yuan, up 0.37% year on year, net profit of 70.19 million yuan, up 10.04% year on year, after deducting non-net profit of 53.8976 million yuan, up 9.61% year on year, with basic earnings of 0.16 yuan per share.
Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
With its stock down 10% over the past month, it is easy to disregard Hunan Fangsheng Pharmaceutical (SHSE:603998). However, stock prices are usually driven by a company's financial performance over
Fangsheng Pharma's Factories Pass GMP Inspection
Hunan Fangsheng Pharmaceutical's (SHA:603998) production lines passed the good manufacturing practice or GMP inspection of China's National Medical Products Administration in Hunan province, the pharm
Fangsheng Pharmaceutical (603998.SH) passed the drug GMP compliance inspection
Fangsheng Pharmaceutical (603998.SH) issued an announcement. The company received the “Drug G...” issued by the Hunan Drug Administration
Fangsheng Pharma Gets 12.1 Million Yuan in Government Grants in January-March
Hunan Fangsheng Pharmaceutical (SHA:603998) obtained government subsidies worth 12.1 million yuan between January and March, the company said in its disclosure on the Shanghai Stock Exchange. The bene
Fangsheng Pharmaceutical (603998.SH): Received a government subsidy of 12.1431 million yuan
Gelonghui, April 7, 丨 Fangsheng Pharmaceutical (603998.SH) announced that the total amount of earnings-related subsidies initially confirmed by the company, its wholly-owned subsidiaries and holding subsidiaries from January 3, 2024 to March 31, 2024 was RMB 12.1431 million, accounting for 4.25% of the company's 2022 audited net profit.
Fangsheng Pharmaceutical (603998.SH): Plans to add 500-700 level-II hospitals to cover 500-700 level-II and above with Xuanqijian bone tablets in 2024
Gelonghui, March 21丨Fangsheng Pharmaceutical (603998.SH) recently said during a survey of institutional investors that in 2024, the company plans to add coverage to 500-700 level-II hospitals with Xuanqijian Bone tablets; 400-500 level-II hospitals and above with garcinia jingxing cough tablets; 400-500 level-II and above hospitals; Strong Loquat Paste (Honey) /Lu will cover 300-400 level-II and above hospitals.
Fangsheng Pharmaceutical (603998.SH): Currently, there are reserves for traditional Chinese medicine research and development projects such as Noliton granules and Hiruron Tongluo tablets
Gelonghui, March 21丨Fangsheng Pharmaceutical (603998.SH) recently said during a survey receiving institutional investors that the company currently has reserves for traditional Chinese medicine research and development projects such as Noriton granules, Hirulongtong tablets, stomach health and pain relief pills, and hemostasis and pain relief granules; among them, stomach health and pain relief pills are currently undergoing phase III clinical trials and are expected to be declared for production in 2025. In addition, a new adult indication study was added to the pediatric Jingxing Cough Relief Granule, which is currently in phase II clinical trials.
Fangsheng Pharmaceutical (603998.SH): Sales of most of the “338 Project” products are growing well
Gelonghui, March 21丨Fangsheng Pharmaceutical (603998.SH) recently said during a survey of institutional investors that judging from the January-February sales situation, sales of most products of the “338 Project” product grew well; the wholly-owned subsidiary Tengwangge Pharmaceutical only began selling strong loquat paste (honey) in late January due to the late arrival of important raw materials (poppy shells); currently, the first quarter has not ended, and the 2023 Spring Festival time and market demand are different from this year, so we still need to keep watching the single quarter results.
Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Shares Climb 31% But Its Business Is Yet to Catch Up
Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) shareholders would be excited to see that the share price has had a great month, posting a 31% gain and recovering from prior weakness. Unfort
Fangsheng Pharmaceutical (603998.SH): Halfway through the increase period, Board Secretary He Shi has increased his holdings by 25,000 shares
Gelonghui, March 8, 丨 Fangsheng Pharmaceutical (603998.SH) announced that as of the disclosure date of this announcement, the implementation period of this increase plan has passed. From December 8, 2023 to March 8, 2024, according to his own funding arrangements and capital market related circumstances, Mr. He Shi, the secretary of the board of directors, increased his holdings by 25,000 shares, accounting for 0.0057% of the company's total shares, with a total increase of RMB 268,300. The implementation of this shareholding increase plan has not yet been completed, and the entities that have increased their holdings will continue to implement this plan to increase their holdings.
Hunan Fangsheng Pharmaceutical's (SHSE:603998) Three-year Earnings Growth Trails the Impressive Shareholder Returns
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make much more than 100% if the company does well. F
Fangsheng Pharmaceutical (603998.SH): Plans to transfer 100% of the shares of Xinpan Biotech, a subsidiary of its wholly-owned subsidiary
Gelonghui, Feb. 27丨Fangsheng Pharmaceutical (603998.SH) announced that the company and its wholly-owned subsidiaries Hunan Nansheng Green Synthetic Pharmaceutical Co., Ltd. and Hunan Xinpan Biotechnology Co., Ltd. have signed an “Equity Transfer Agreement” with Hunan Zhengshen Technology Co., Ltd. and natural person Mr. Liang Buge. The parties agreed to transfer 100% of Xinpan Biotech's shares held by Luhe Pharmaceutical to Zhengshen Technology for RMB 52 million. According to the “Equity Transfer Agreement”, after paying the second equity transfer payment, Zhengshen Technology will apply for a loan from the bank using Xinpan Biotech's assets as collateral, and the loan obtained will be used to pay to Luhe Pharmaceutical
Investors Don't See Light At End Of Hunan Fangsheng Pharmaceutical Co., Ltd.'s (SHSE:603998) Tunnel And Push Stock Down 29%
The Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998) share price has fared very poorly over the last month, falling by a substantial 29%. Longer-term shareholders would now have taken a real
Fangsheng Pharmaceutical (603998.SH): Stomach health and pain relief pills are currently undergoing phase III clinical trials and are expected to be declared for production in 2025
Gelonghui, January 29丨Fangsheng Pharmaceutical (603998.SH) recently said during a survey receiving institutional investors that the company currently has reserves for traditional Chinese medicine research and development projects such as Noriton granules, stomach health and pain relief pills, Hirulong tablets, hemostatic pain relief granules, and anti-cancer tablets; among them, stomach health and pain relief pills are currently undergoing phase III clinical trials and are expected to be declared for production in 2025.
Fangsheng Pharmaceutical (603998.SH): Key products of Tengwangge Pharmaceutical include Strong Loquat Cream (Honey), Strong Loquat Lotion, and Ginseng and Astragalus Antler Oral Liquid
Gelonghui, January 29丨Fangsheng Pharmaceutical (603998.SH) recently said during a survey reception from institutional investors that Tengwangge Pharmaceutical's key products include Strong Loquat Cream (Honey), Strong Loquat Lotion, and Ginseng and Astragalus Antler Oral Liquid. Among them, strong loquat cream (honey) is a national medical insurance class A variety, a national base drug, a nationally exclusive dosage form, and is included in the “Chinese Pharmacopoeia” and has an exclusive patented honey refining process. Over the years since its launch, it has now been used in nearly 1,500 level hospitals and more than 7,000 primary medical institutions across the country. Its efficacy and safety have been widely recognized by clinicians and patients, and it has been widely recognized by “Cough
Fangsheng Pharmaceutical (603998.SH): In 2023, Tengwangge Pharmaceutical products achieved a steady increase in sales revenue and profit
Gelonghui, January 29丨Fangsheng Pharmaceutical (603998.SH) recently said during a survey receiving institutional investors that in 2023, Tengwangge Pharmaceutical products achieved a steady increase in sales revenue and profit; in the first three quarters, Tengwangge Pharmaceutical had achieved operating income of 160 million yuan and net profit of nearly 30 million yuan, which exceeded the full year of 2022; however, its annual performance still did not meet the company's annual budget target, mainly because its main product, Strong Loquat Cream (Honey) /Lu, showed a strong trend of supply and sales, leading to the early production and use of one of the main raw materials. The fourth quarter was not updated in time
The Recent CN¥712m Market Cap Decrease Is Likely to Have Disappointed Insiders Invested in Hunan Fangsheng Pharmaceutical Co., Ltd. (SHSE:603998)
Key Insights Significant insider control over Hunan Fangsheng Pharmaceutical implies vested interests in company growth 50% of the business is held by the top 6 shareholders Institutions own 29%
Analysis
Price Target
No Data
